Literature DB >> 9062506

The longitudinal course of psychopathology in Cushing's syndrome after correction of hypercortisolism.

L D Dorn1, E S Burgess, T C Friedman, B Dubbert, P W Gold, G P Chrousos.   

Abstract

Endogenous Cushing's syndrome (CS) is associated with significant psychopathology during the course of the disease. The purpose of this study was to evaluate the psychological and endocrine status of patients with CS after correction of their hypercortisolism. Thirty-three patients with active CS were examined before and at 3 months (28 patients), 6 months (25 patients), and 12 months (29 patients) after correction of hypercortisolism. Before cure, 66.7% of the patients had significant psychopathology, with the predominant diagnosis of atypical depressive disorder (AD) in 51.5% and/or major affective disorder in 12%. After cure, overall psychopathology decreased significantly to 53.6% at 3 months, 36% at 6 months, and 24.1% at 12 months, when there was a parallel recovery of the hypothalamic-pituitary-adrenal axis assessed by serial morning ACTH stimulation tests. There was an inverse correlation between psychological recovery and baseline morning cortisol, but no correlation with ACTH-stimulated cortisol values at 60 min. AD continued to be the prevailing diagnosis after correction of hypercortisolism, whereas the frequency of suicidal ideation and panic increased. The presence of AD before and after correction of hypercortisolism might be due to glucocorticoid-induced suppression of hypothalamic CRH secretion. The slight increase in the incidence of panic after correction of hypercortisolism might be due to a decreased glucocorticoid restraint at the central arousal/sympathetic catecholaminergic system. We conclude that CS is associated with AD symptomatology, which gradually improves with time after correction of hypercortisolism. Health care providers should be aware of changes in symptomatology, including suicidal ideation and panic attacks, that occur in a subgroup of patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9062506     DOI: 10.1210/jcem.82.3.3834

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  53 in total

1.  Is 11beta-hydroxysteroid dehydrogenase type 1 a good therapeutic target for blockade of glucocorticoid actions?

Authors:  George P Chrousos
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-19       Impact factor: 11.205

Review 2.  Beyond fast food and slow motion: weighty contributors to the obesity epidemic.

Authors:  G Cizza; K I Rother
Journal:  J Endocrinol Invest       Date:  2011-12-15       Impact factor: 4.256

3.  A pilot randomized, single-blind, placebo-controlled trial of traditional acupuncture for vasomotor symptoms and mechanistic pathways of menopause.

Authors:  Jeannette M Painovich; Chrisandra L Shufelt; Ricardo Azziz; Yuching Yang; Mark O Goodarzi; Glenn D Braunstein; Beth Y Karlan; Paul M Stewart; C Noel Bairey Merz
Journal:  Menopause       Date:  2012-01       Impact factor: 2.953

Review 4.  Characterization of persistent and recurrent Cushing's disease.

Authors:  Nina K Sundaram; Alessia Carluccio; Eliza B Geer
Journal:  Pituitary       Date:  2014-08       Impact factor: 4.107

5.  Computerized Analysis of Brain MRI Parameter Dynamics in Young Patients With Cushing Syndrome-A Case-Control Study.

Authors:  Amit Tirosh; Harish RaviPrakash; Georgios Z Papadakis; Christina Tatsi; Elena Belyavskaya; Lyssikatos Charalampos; Maya B Lodish; Ulas Bagci; Constantine A Stratakis
Journal:  J Clin Endocrinol Metab       Date:  2020-05-01       Impact factor: 5.958

6.  Do glucocorticoids induce addiction in humans?

Authors:  R Giordano; F Guaraldi; M Mazzoli; E Ghigo
Journal:  J Endocrinol Invest       Date:  2017-03-25       Impact factor: 4.256

7.  Extensive clinical experience: Hypothalamic-pituitary-adrenal axis recovery after adrenalectomy for corticotropin-independent cortisol excess.

Authors:  Maria Daniela Hurtado; Tiffany Cortes; Neena Natt; William F Young; Irina Bancos
Journal:  Clin Endocrinol (Oxf)       Date:  2018-07-23       Impact factor: 3.478

Review 8.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

9.  Quality of life in children and adolescents 1-year after cure of Cushing syndrome: a prospective study.

Authors:  Margaret F Keil; Deborah P Merke; Roma Gandhi; Edythe A Wiggs; Kathy Obunse; Constantine A Stratakis
Journal:  Clin Endocrinol (Oxf)       Date:  2008-12-17       Impact factor: 3.478

10.  Treatment of severe psychosis due to ectopic Cushing's syndrome.

Authors:  Y M Bilgin; H E van der Wiel; H R Fischer; W W De Herder
Journal:  J Endocrinol Invest       Date:  2007-10       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.